Detalhe da pesquisa
1.
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
N Engl J Med
; 388(4): 319-332, 2023 01 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36511784
2.
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment.
Future Oncol
; 20(12): 717-726, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38088119
3.
ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Future Oncol
; 16(10): 517-523, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-32207333
4.
Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: post-hoc analysis of a large clinical trial safety database.
Haematologica
; 2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38426293
5.
Treatment of adult acute myeloid leukemia.
Duodecim
; 132(16): 1465-73, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-29188934
6.
[Adult acute lymphoblastic leukemia - 20-year treatment results at TYKS]. / Aikuisten akuutti lymfaattinen leukemia - 20 vuoden hoitotulokset TYks:ssa.
Duodecim
; 130(7): 714-20, 2014.
Artigo
em Fi
| MEDLINE | ID: mdl-24772789
7.
Health-related quality of life outcomes associated with zanubrutinib versus ibrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from the ALPINE Trial.
Curr Med Res Opin
; : 1-7, 2023 Sep 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37752892
8.
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.
J Clin Oncol
; 41(5): 1035-1045, 2023 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36395435